

Distribution Frequency Monthly


Expense Ratio 0.35%

Strategy Covered Call

### Summary

The return on the ETP Securities is linked to the performance of the LS Silver Yield Options-Based Income Strategy. The Investment Strategy seeks to generate monthly income by selling options on iShares Silver Trust (SLV) and paying a return based on the cash held.

### Strategy



### Key Benefits

#### ▶ Maximum Income

Enhanced monthly income from premiums received through options selling and a return on cash.

#### ▶ Upside Exposure

Participation in the upside potential of leading tech stocks up to the options' strike price.

#### ▶ Downside Protection

Income generated from selling options may help cushion against market downturns.

### Key Risks

- ▶ The covered call strategy caps the upside potential of the underlying stocks.
- ▶ While the premium income can offset some losses, the underlying stocks can still decline in value, leading to potential capital losses.
- ▶ Please see the 'Risks Factors' section of the base prospectus of Leverage Shares plc relevant to an investor's jurisdiction (the "Relevant Prospectus") for a more detailed discussion of the potential risks associated with an investment in this product.

### Product Information

Product Name	<b>IncomeShares Silver+ Yield ETP</b>
Issuer	<b>Leverage Shares PLC</b>
Base Currency	<b>USD</b>
ISIN	<b>XS3068774614</b>
Inception Date	<b>26 June 2025</b>
Management Fee	<b>0.35%</b>
Strategy	<b>Covered Call</b>
Countries Available	<b>United Kingdom, Italy, Germany, France, Spain, Netherlands, Ireland, Poland, Belgium, Sweden, Norway, Austria</b>
SIPP/ISA Eligible	<b>Yes</b>
UCITS Eligible	<b>Yes</b>
Sec871(m)	<b>Not Applicable (see FAQs)</b>

### Distributions

Frequency	<b>Monthly</b>
-----------	----------------

*\*Investors should refer to the Prospectus ([www.leverageshares.com](http://www.leverageshares.com)) for a more complete description of the product, service providers and relevant regulatory factors.*

Country	Exchange	Base Currency	Trading Currency	Exchange Code	ISIN	SEDOL	BBG Ticker	RIC	WKN	Listing Date
UK	London Stock Exchange	USD	USD	SLVY	XS3068774614	BP7M092	SLVY LN	SLVY.L	-	27/06/2025
UK	London Stock Exchange	USD	GBP	SLVI	XS3068774614	BP6WQ54	SLVI LN	SLVI.L	-	27/06/2025
Netherlands	Euronext Amsterdam	USD	EUR	SLVY	XS3068774614	BR4ZXQ6	SLVY NA	SLVY.AS	-	15/10/2025
Germany	Frankfurt Stock Exchange	USD	EUR	YSLV	XS3068774614	BP7M084	YSLV GY	YSLV.DE	A4AN02	15/7/2025

## Contact Information

Contact us via email at [info@leverageshares.com](mailto:info@leverageshares.com) or on Twitter at @LeverageShares. More information on Leverage Shares can be found online at [www.leverageshares.com](http://www.leverageshares.com).

## Disclaimer

Leverage Shares ETPs are only intended for sophisticated traders who understand the associated risks and are able to monitor their positions on an intraday basis. Please consult an investment adviser to determine whether or not the products are suitable for you. Traders should also review the Relevant Prospectus (as defined below) and the Leverage Shares educational materials carefully before considering the ETPs.

## No investment advice

Leverage Shares PLC is required by the FCA to clarify that it is not acting for you in any way in relation to the investment or investment activity to which this financial promotion relates. In particular, LEVERAGE SHARES PLC will not provide any investment services to you and/or advise you on the merits of, or make any recommendation to you in relation to, the terms of any transaction. No representative of LEVERAGE SHARES PLC is authorised to behave in any way which would lead you to believe otherwise. LEVERAGE SHARES PLC is not, therefore, responsible for providing you with the protections afforded to its clients and you should seek your own independent legal, investment and tax or other advice as you see fit.

## No offer for sale

The information contained in this financial promotion is neither an offer for sale nor a solicitation of an offer to buy securities. This financial promotion should not be used as the basis for any investment decision.

## Risk Warnings

The value of an investment in ETPs may go down as well as up and past performance is not a reliable indicator of future performance. An investment in ETPs is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs offering daily leveraged or daily short exposures ("Leveraged ETPs") are products which feature specific risks that prospective investors should understand before investing in them.

Securities issued by the Issuer are products involving a significant degree of risk and may not be suitable for all types of investor. Any decision to invest should be based on the information contained in the Relevant Prospectus of the Issuer (or any supplements thereto) which includes, inter alia, information on certain risks associated with an investment. The price of any securities may go up or down and an investor may not get back the amount invested. Securities are priced in US Dollars/Euros/Pounds and the value of the investment in other currencies will be affected by exchange rate movements.

Short and leveraged exchange-traded products are only intended for investors who understand the risks involved in investing in a product with short and/or leveraged exposure and who intend to invest on a short-term basis. Any investment in short and/or leveraged products should be monitored on a daily basis to ensure consistency with your investment strategy. You should understand that investments in short and/or leveraged exchange-traded products held for a period of longer than one day may not provide returns equivalent to the return from the relevant unleveraged investment multiplied by the relevant leverage factor.

Potential losses in short and/or leveraged exchange-traded products may be magnified in comparison to investments that do not incorporate these strategies. Please refer to the section entitled "Risk Factors" in the relevant prospectus for further details of these and other risks associated with an investment in short and/or leveraged exchange traded products. You should consult an independent investment adviser prior to making an investment in short and/or leveraged exchange-traded products in order to determine its suitability to your circumstances.

## Prospectus

A base prospectus has been approved by the Central Bank of Ireland as competent authority under Regulation (EU) 2017/1129 with respect to the offer and listing of ETPs in Ireland and certain other EU jurisdictions listed below (the "EU Prospectus"). A base prospectus has been approved by the Financial Conduct Authority as competent authority under the United Kingdom's version of Regulation (EU) No 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 with respect to the offer and listing of ETPs in the United Kingdom (the "UK Prospectus"). The "Relevant Prospectus" means the EU Prospectus or the UK Prospectus, as applicable.

The Central Bank of Ireland has delivered to the regulators listed below certificates of approval attesting that the EU Prospectus has been drawn up in accordance with Article 25 of Regulation (EU) 2017/1129.

The EU Prospectus (and any supplements thereto) of the Issuer has been passported from Ireland into Italy (Commissione Nazionale per la Società e la Borsa), Germany (Bundesanstalt für Finanzdienstleistungsaufsicht), France (Autorité des Marchés Financiers), Spain (Comisión Nacional del Mercado de Valores), the Netherlands (the Autoriteit Financiële Markten), Poland (Komisja Nadzoru Finansowego), Belgium (Belgian Financial Services and Markets Authority) and Austria (Finanzmarktaufsichtsbehörde).

Investors should read the Relevant Prospectus of the Issuer before investing and should refer to the section of the Relevant Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product.